Bad Berka Heart Rhythm Registry of Patients With or at Risk of Arrhythmias Treated at Heart Center Bad Berka
Launched by ZENTRALKLINIK BAD BERKA · Jun 12, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The Bad Berka Heart Rhythm Registry (2B2R) is a study taking place at the Heart Center Bad Berka. It aims to gather information about patients who have heart rhythm issues, known as arrhythmias, or are at risk for them. This research will help doctors understand how safe different treatments are and how well they work over time. The study will also look at new treatment methods, like pulsed field ablation (PFA), which uses energy to treat heart conditions, and conduction system pacing, which is a way to improve heart beats.
To join this study, participants must be at least 18 years old and either have a diagnosed arrhythmia or be at risk for one, and they should be receiving treatment at the Heart Center Bad Berka. It's important that they are willing to provide informed consent, meaning they agree to participate and understand what it involves. Participants will be monitored to see how they respond to treatment, helping to improve future care for others with similar heart conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • At risk of or with documented cardiac arrhythmia undergoing medical or interventional therapy at the Heart Center Bad Berka
- • Informed consent obtained
- Exclusion Criteria:
- • Inability or unwillingness to provide informed consent
- • Participation in another interventional trial that precludes registry inclusion
About Zentralklinik Bad Berka
Zentralklinik Bad Berka is a leading healthcare institution in Germany, renowned for its commitment to high-quality patient care and advanced medical research. With a focus on innovative treatment approaches and comprehensive clinical services, the clinic specializes in various medical fields, including rehabilitation and specialized care for chronic conditions. As a dedicated clinical trial sponsor, Zentralklinik Bad Berka actively participates in the development of new therapies and medical technologies, collaborating with academic institutions and industry partners to enhance patient outcomes and contribute to the advancement of medical science. Their rigorous adherence to ethical standards and regulatory compliance underscores their mission to improve healthcare delivery through evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bad Berka, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported